Claims for Patent: 10,031,127

Summary for Patent: 10,031,127

Title:	Method for separating aggregates of malignant cells and aggregates from stromal cells of a malignant tumour tissue sample
Abstract:	An ex vivo malignant tumor tissue sample is cleaned, comminuted, suspended in culture medium, subjected to a treatment with collagenase and the collagenase decomposition product is centrifuged. The pellet obtained is re-suspended in culture medium by an absorption instrument, is absorbed and returned several times and transferred to a culture vessel. The re-suspension thus obtained is analyzed under a microscope with phase optics for cell aggregates, which, due to the phenotypic appearance thereof, are identifiable as an aggregate of malignant cells or as an aggregate of endothelial cells or as an aggregate of fibroblasts, and the identified cell aggregates are separated.
Inventor(s):	Granzow; Christof (Heidelberg, DE)
Assignee:	FLACOD GmbH (Heidelberg, DE)
Application Number:	14/372,243
Patent Claims:	1. A method for separating clusters of malignant cells and clusters of stromal cells of a malignant tumor tissue sample ex vivo, comprising the following steps in order: (a) purifying and mincing the malignant tumor tissue sample, (b) suspending the minced tissue in culture medium, (c) subjecting the suspension obtained in (b) to an exclusive treatment solely with collagenase for a partial collegenase digestion, wherein Clostridium histolyticum collagenase is used in a concentration of 200 CDU to 250 CDU per mL at approximately 36.degree. C. to 37.degree. C. for a period of approximately 4 to 5 hours, (d) centrifuging the collagenase decomposition product obtained in (c) to obtain a pellet, (e) separating the pellet obtained in (d) from the supernatant, (f) decomposing the pellet from (e) and resuspending the resulting decomposed matter in culture medium by an aspiration device, the resuspension step comprising aspirating, returning and sucking in again several times, and subsequently transferring the resuspension to a culture vessel, (g) analyzing the resuspension obtained in (f) with regard to at least one cell cluster with a microscope, wherein the at least one cell cluster can be identified either on the basis of its phase-optical appearance either as a cluster of malignant cells, or as a cluster of endothelial cells, or as a cluster of fibroblasts, and (h) separating the cell clusters identified in (g). 2. The method according to claim 1, wherein the collagenase used in step (c) is used in a concentration of approximately 230 CDU/mL. 3. The method according to claim 1, wherein in step (g) the resuspension is analyzed with regard to cell clusters of malignant cells and also with regard to cell clusters of fibroblasts and/or cell clusters of endothelial cells, and wherein the cell clusters identified are aspirated separately, and each type of clusters is transferred to a separate culture vessel. 4. The method according to claim 1, wherein in step (g) the resuspension is subjected to a density gradient centrifugation in a separation solution of sucrose polymer, where the clusters of malignant cells sediment at higher concentrations of the sucrose polymer than the clusters of fibroblast or of endothelial cells. 5. The method according to claim 1, wherein in step (g) the resuspension is transferred to a separation chamber for centrifugal elutriation and then elutriated, wherein the clusters of malignant cells collect at higher flow rates than the clusters of fibroblasts or the clusters of endothelial cells. 6. The method according to claim 1, wherein the method is a precursor method for a method for testing the sensitivity and possible resistance of the cells of a malignant tumor tissue sample ex vivo for a known chemotherapeutic and/or radiotherapeutic agent. 7. The method for testing the response of malignant cells of a malignant tumor tissue sample ex vivo for a known chemotherapeutic and/or radiotherapeutic agent, wherein the malignant tumor tissue sample is first subjected to a method according to claim 1, and only the clusters of malignant cells thereby identified are used in the method for evaluation/testing. 8. The method according to claim 7, wherein the method for testing comprises the following measures: i) transferring the identified clusters of malignant cells to containers with a coating of extracellular matrix components, plating them out on this coating and exposing them to the chemotherapeutic and/or radiotherapeutic agent, ii) analyzing the number of cells and/or the number of colonies, preferably after performing a cytokeratin staining, iii) wherein the cell culture medium used in steps i) and ii) contains less than 100 nmol of flavin per 1 liter and is free of phenol red, iv) and wherein steps i) and ii) are performed in the absence of light of wavelengths below 520 nm, v) determining the IC50 value for the chemotherapeutic or radiotherapeutic agent or for the combination of chemotherapeutic and radiotherapeutic agent. 9. A method for testing the growth-inhibiting effect of a known chemotherapeutic and/or radiotherapeutic agent on a malignant tumor tissue sample ex vivo, whereby the malignant tumor tissue sample is exposed to the chemotherapeutic and/or radiotherapeutic agent and then the number of cells and/or cell colonies is analyzed and finally the IC50 value of the chemotherapeutic or radiotherapeutic agent or the combination of chemotherapeutic and radiotherapeutic agent is determined, and wherein the malignant tumor tissue sample, before being exposed to the chemotherapeutic and/or radiotherapeutic agent, is decomposed into clusters of stromal cells and of malignant cells by a method according to claim 1, and only the clusters of malignant cells are incubated with the chemotherapeutic and/or radiotherapeutic agent and then analyzed with regard to the IC50 value of the agent used. 10. The method according to claim 3, wherein the separated clusters of endothelial cells are subjected to a method for testing for the effect of substances which inhibit angioneogenesis.

Details for Patent 10,031,127

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2032-02-28